This company has been marked as potentially delisted and may not be actively trading. I-Mab (IMAB) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock IMAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a ...October 29, 2025 | markets.businessinsider.comI-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech PlatformOctober 29, 2025 | globenewswire.comI-Mab - Depositary Receipt (IMAB) Price Target Increased by 19.05% to 8.50October 29, 2025 | msn.comBTIG Reiterates I-Mab - Depositary Receipt (IMAB) Buy RecommendationOctober 24, 2025 | msn.comI-MAB Reports Positive Phase I Results for Givastomig in Gastroesophageal CancerOctober 24, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMABOctober 23, 2025 | prnewswire.comI-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025October 22, 2025 | globenewswire.comI-Mab tumbles after announcing new business modelOctober 17, 2025 | msn.comI-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth TranscriptOctober 17, 2025 | seekingalpha.comI-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge BiosciencesOctober 16, 2025 | globenewswire.comI-Mab Biopharma Stock: Caution Warranted After Huge SurgeOctober 14, 2025 | seekingalpha.comI-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ConferenceOctober 14, 2025 | globenewswire.comI-Mab's (NASDAQ:IMAB) market cap surged US$52m last week, individual investors who have a lot riding on the company were rewardedOctober 11, 2025 | uk.finance.yahoo.comLeerink Partners Initiates Coverage of I-Mab - Depositary Receipt (IMAB) with Outperform RecommendationOctober 4, 2025 | msn.comI-Mab initiated with an Outperform at LeerinkOctober 3, 2025 | msn.comI-Mab to Vote on Name Change to NovaBridge BiosciencesSeptember 25, 2025 | msn.comI-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric CancerSeptember 23, 2025 | msn.comI-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By MarketSeptember 10, 2025 | seekingalpha.comBTIG Initiates Coverage of I-Mab - Depositary Receipt () (IMAB) with Buy RecommendationSeptember 9, 2025 | msn.comI-Mab initiated with a Buy at BTIGSeptember 9, 2025 | msn.comI-Mab Announces Leadership Changes and Accelerated Investment in GivastomigSeptember 9, 2025 | msn.comI-Mab announces accelerated investment in givastomig programSeptember 9, 2025 | msn.comI-Mab Announces Acceleration of Givastomig Investment and Leadership AppointmentsSeptember 9, 2025 | markets.businessinsider.comI-Mab to accelerate investment in givastomigSeptember 9, 2025 | msn.comI-Mab Insiders Land Bargain With Gains Of US$5.0mAugust 31, 2025 | finance.yahoo.comI-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development CommitteeAugust 25, 2025 | globenewswire.comI-Mab Biopharma: I-Mab Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 21, 2025 | finanznachrichten.deI-Mab to Participate in September Investor ConferencesAugust 21, 2025 | globenewswire.comI-Mab Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 20, 2025 | tmcnet.comI-Mab price target raised to $6 from $5 at NeedhamAugust 20, 2025 | msn.comI-Mab Reports Strong Financials and Clinical Progress in August 2025August 20, 2025 | msn.comI MAB (ADS) options imply 11.8% move in share price post-earningsAugust 19, 2025 | msn.comEverest Medicines announces strategic equity investment in I-MabAugust 1, 2025 | msn.comEverest Medicines Expands Strategic Investment in I-MABAugust 1, 2025 | prnewswire.comI-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary SharesAugust 1, 2025 | globenewswire.comI-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge HealthJuly 17, 2025 | globenewswire.comI-Mab to Present at the BTIG Virtual Biotechnology ConferenceJuly 14, 2025 | finance.yahoo.comI-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025July 9, 2025 | msn.comI-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric ... - NasdaqJuly 4, 2025 | nasdaq.comI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025July 2, 2025 | globenewswire.comI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - MorningstarJuly 2, 2025 | morningstar.comMI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer ResearchJune 30, 2025 | globenewswire.comI-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025June 26, 2025 | globenewswire.comI-Mab Biopharma: I-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 13, 2025 | finanznachrichten.deI-Mab Regains Nasdaq Compliance with Minimum Bid PriceJune 12, 2025 | tipranks.comI-Mab regains Nasdaq compliance as shares maintain $1 minimum bidJune 12, 2025 | investing.comI-Mab to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 3, 2025 | finance.yahoo.comI-Mab Advances Givastomig in Gastric Cancer with Promising Clinical DataJune 2, 2025 | tipranks.comI-Mab stock surges on Lucid Capital’s buy rating initiationMay 29, 2025 | za.investing.comI-Mab stock surges on Lucid Capital's buy rating initiationMay 28, 2025 | investing.com Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMAB Media Mentions By Week IMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMAB News Sentiment▼0.000.45▲Average Medical News Sentiment IMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMAB Articles This Week▼03▲IMAB Articles Average Week Get the Latest News and Ratings for IMAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for I-Mab and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Iovance Biotherapeutics News Taysha Gene Therapies News GH Research News Ardelyx News Damora Therapeutics, Inc. Common Stock News Recursion Pharmaceuticals News Monte Rosa Therapeutics News Precigen News Nuvation Bio News Atai Beckley News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMAB) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredOne coin wired into Elon's visionSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
